Medical School · Year 4 · Critical Care · includes a quiz and discussion video
Seminar 5: ICU Nutrition and Sedation
Year 4: Critical Care Elective
Learning Objectives
By the end of this seminar, students will be able to:
- Assess nutritional status and calculate caloric and protein requirements for critically ill patients
- Implement enteral and parenteral nutrition strategies with appropriate route selection and monitoring
- Apply analgesia-first sedation principles using validated assessment tools and appropriate medication selection
- Prevent, diagnose, and manage ICU delirium using evidence-based protocols
- Implement early mobilization programs to prevent ICU-acquired weakness
- Integrate components of the ABCDEF bundle to promote patient liberation from ICU care
I. Nutritional Assessment in Critical Illness
Nutritional status assessment in the ICU begins with evaluation of pre-illness nutritional state and current metabolic requirements. The patient history should establish prior dietary intake, recent weight changes, and presence of conditions affecting nutrition such as malignancy, chronic illness, or gastrointestinal disease. Actual body weight compared to usual and ideal body weight identifies patients who are malnourished or at nutritional risk. Physical examination findings of muscle wasting, loss of subcutaneous fat stores, and edema provide clinical assessment of nutritional status. Validated screening tools including the Nutritional Risk Screening 2002 (NRS-2002) and the Nutrition Risk in Critically Ill (NUTRIC) score identify patients at high nutritional risk who may benefit most from aggressive nutritional support.
Laboratory markers have limited utility in assessing acute nutritional status in critically ill patients. Albumin reflects synthetic capacity and is affected by inflammation, fluid status, and catabolism rather than serving as a reliable nutrition marker. Prealbumin has a shorter half-life and may reflect recent nutritional changes, but is similarly affected by inflammation and illness severity. These markers should not be used to guide initiation of nutrition or assess adequacy of nutritional support. C-reactive protein elevation indicates inflammation and helps contextualize low albumin and prealbumin values. Clinical assessment and caloric balance tracking provide more actionable information than laboratory markers.
Caloric requirements can be estimated using predictive equations or measured using indirect calorimetry. Predictive equations typically target 25-30 kcal/kg/day for most critically ill patients, though individual variation is substantial. Indirect calorimetry measuring oxygen consumption and carbon dioxide production provides the gold standard for determining individual caloric needs, though availability is limited. Overfeeding causes hyperglycemia, hepatic steatosis, and increased carbon dioxide production, while underfeeding leads to protein catabolism and impaired wound healing. Protein requirements are elevated in critical illness, with targets of 1.2-2.0 g/kg/day for most patients. Special populations including obese patients and those with renal failure require adjusted calculations.
Timing of nutritional support initiation affects outcomes in critically ill patients. Early enteral nutrition within 24-48 hours of ICU admission is associated with improved outcomes and is recommended for most patients. Initial trophic feeding at low rates (10-20 mL/hour) provides gut stimulation and may be advanced to goal over 24-72 hours based on tolerance. Delayed initiation may be appropriate in patients with hemodynamic instability requiring high-dose vasopressors, where gut hypoperfusion increases risk of non-occlusive mesenteric ischemia. Route selection prioritizes enteral nutrition when the gastrointestinal tract is functional; parenteral nutrition is reserved for patients who cannot receive enteral feeding.
<image>Figure 1. Nutritional Assessment in Critical Illness. Panel A describes assessment components including history, weight comparison, physical examination, and validated screening tools (NRS-2002, NUTRIC). Panel B discusses laboratory marker limitations, noting that albumin and prealbumin reflect inflammation more than nutrition. Panel C presents caloric requirement estimation using predictive equations (25-30 kcal/kg) and indirect calorimetry, with protein targets of 1.2-2.0 g/kg/day. Panel D outlines timing recommendations for early enteral nutrition within 24-48 hours with considerations for delayed initiation in hemodynamically unstable patients.</image>
II. Enteral Nutrition
Enteral access options range from simple bedside placement to interventional or surgical approaches depending on clinical needs. Nasogastric tubes represent the standard initial access for most patients, easily placed at bedside and suitable for short-term use. Post-pyloric feeding via nasoduodenal or nasojejunal tubes may benefit patients with gastroparesis, high aspiration risk, or gastric feeding intolerance. Percutaneous endoscopic gastrostomy (PEG) or jejunostomy (PEJ) tubes provide long-term access for patients expected to require tube feeding beyond 4 weeks. Surgical gastrostomy or jejunostomy may be placed during abdominal operations or when endoscopic access is not feasible.
Formula selection is guided by patient characteristics and clinical requirements. Standard polymeric formulas meet the needs of most critically ill patients and contain intact protein, carbohydrates, and fats with fiber. Immune-modulating formulas containing arginine, omega-3 fatty acids, and nucleotides may benefit select surgical and trauma patients, though evidence in medical ICU patients is limited. Disease-specific formulas are available for renal failure (lower electrolytes, concentrated volume), hepatic encephalopathy (branched-chain amino acids), and pulmonary failure (higher fat, lower carbohydrate to reduce CO2 production). Semi-elemental or elemental formulas with pre-digested protein may improve absorption in patients with pancreatic insufficiency or short bowel syndrome.
Complications of enteral nutrition require monitoring and management. Aspiration represents the most serious complication, with risk reduced by head of bed elevation to 30-45 degrees, consideration of post-pyloric feeding, and attention to gastric residuals when clinically significant. Diarrhea is common and requires evaluation for Clostridium difficile infection, hyperosmolar formula, medication effects, and malabsorption; fiber-containing formulas and probiotic adjuncts may help. Constipation from immobility and opioid use may require bowel regimens. High gastric residual volumes historically prompted feeding interruption, though recent evidence suggests that routine monitoring and holding for moderate residuals does not improve outcomes; prokinetic agents may help patients with documented gastroparesis.
Monitoring ensures adequate delivery and identifies complications early. Gastric residual volume checking, if performed, should not routinely interrupt feeding for volumes below 500 mL unless accompanied by clinical signs of intolerance. Bowel function assessment including presence of bowel sounds, stool output, and abdominal examination guides tolerance evaluation. Blood glucose monitoring every 4-6 hours initially identifies hyperglycemia requiring insulin therapy. Electrolyte monitoring identifies abnormalities, particularly in patients at risk for refeeding syndrome. Actual versus prescribed calorie delivery should be tracked, as interruptions for procedures and intolerance commonly cause significant deficits.
<image>Figure 2. Enteral Nutrition. Panel A presents access options including nasogastric (standard short-term), post-pyloric (gastroparesis, aspiration risk), and PEG/PEJ (long-term over 4 weeks). Panel B describes formula selection including standard polymeric, immune-modulating, disease-specific (renal, hepatic, pulmonary), and elemental formulas. Panel C addresses complications including aspiration (head elevation, post-pyloric feeding), diarrhea (C. diff evaluation, fiber), constipation, and gastric residuals. Panel D outlines monitoring including residual volumes, bowel function, glucose, electrolytes, and caloric delivery tracking.</image>
III. Parenteral Nutrition
Parenteral nutrition is indicated when enteral nutrition is not possible or insufficient to meet nutritional requirements. Non-functioning gastrointestinal tract from bowel obstruction, ileus, or anastomotic leak prevents enteral feeding. High-output fistulas may require parenteral nutrition to bypass the fistula while providing adequate nutrition. Short bowel syndrome with insufficient absorptive capacity necessitates parenteral supplementation or complete parenteral nutrition. Severe acute pancreatitis in the early phase historically required bowel rest, though current evidence supports early enteral nutrition when tolerated; parenteral nutrition is reserved for patients who cannot advance enteral feeding.
The components of parenteral nutrition provide complete macronutrient and micronutrient support. Dextrose (glucose) serves as the primary energy source, typically providing 50-70% of non-protein calories. Amino acids provide the protein source at concentrations of 1.0-2.0 g/kg/day. Lipid emulsions supply essential fatty acids and concentrated calories, typically providing 15-30% of total calories; newer formulations with fish oil and medium-chain triglycerides may have advantages over traditional soybean-based emulsions. Electrolytes including sodium, potassium, chloride, phosphorus, calcium, and magnesium are added based on daily requirements and ongoing losses. Vitamins and trace elements are included or supplemented separately.
Complications of parenteral nutrition require prevention, monitoring, and management. Hyperglycemia occurs frequently and requires insulin therapy to maintain glucose below 180 mg/dL; excessive dextrose infusion rates worsen hyperglycemia and should be avoided. Catheter-related bloodstream infection risk is minimized through sterile insertion, dedicated parenteral nutrition lumens, and prompt line removal when infection is suspected. Liver dysfunction including steatosis and cholestasis occurs with prolonged parenteral nutrition; cycling the infusion over 12-18 hours rather than 24 hours and minimizing lipid infusion may help. Refeeding syndrome poses risk to malnourished patients receiving sudden nutritional repletion.
Refeeding syndrome represents a potentially fatal complication when nutrition is rapidly initiated in malnourished patients. The underlying mechanism involves intracellular shift of phosphorus, potassium, and magnesium as glucose stimulates insulin release and cellular uptake. At-risk patients include those with chronic malnutrition, anorexia nervosa, alcoholism, prolonged fasting, and recent major weight loss. Prevention requires identifying at-risk patients, starting nutrition at low rates (10-20 kcal/kg/day), and advancing gradually over several days. Monitoring electrolytes closely and replacing phosphorus, potassium, and magnesium aggressively prevents complications. Thiamine supplementation before carbohydrate administration prevents Wernicke encephalopathy.
<image>Figure 3. Parenteral Nutrition. Panel A lists indications including non-functioning GI tract, high-output fistulas, short bowel syndrome, and severe pancreatitis when enteral nutrition fails. Panel B describes components: dextrose (energy), amino acids (protein), lipids (essential fatty acids and calories), electrolytes, and vitamins/trace elements. Panel C addresses complications including hyperglycemia (insulin, limit dextrose), catheter infection (sterile technique, dedicated lumen), and liver dysfunction (cycling, limit lipids). Panel D presents refeeding syndrome pathophysiology, at-risk populations, prevention through gradual advancement, electrolyte monitoring, and thiamine supplementation.</image>
IV. Pain Management in the ICU
Pain assessment in critically ill patients requires adapted approaches for those unable to self-report. The Numeric Rating Scale (NRS) asking patients to rate pain 0-10 remains the gold standard for communicative patients. For non-communicative patients, validated behavioral tools provide objective assessment. The Behavioral Pain Scale (BPS) evaluates facial expression, upper limb movements, and compliance with mechanical ventilation, scoring 3-12 with scores above 6 indicating significant pain. The Critical-Care Pain Observation Tool (CPOT) assesses facial expression, body movements, muscle tension, and vocalization or ventilator compliance, scoring 0-8 with scores above 3 indicating pain. Regular assessment every 4 hours or with any clinical change ensures adequate pain control.
The analgesia-first approach prioritizes pain management before sedation, recognizing that uncontrolled pain causes agitation that may be inappropriately treated with sedatives. The endotracheal tube itself is a significant source of discomfort that cannot be eliminated but can be managed with analgesia. Procedural pain from suctioning, turning, and wound care requires preemptive analgesia. Multimodal analgesia combining opioids with non-opioid adjuncts reduces opioid requirements and side effects. Regional anesthesia including epidural analgesia for thoracic and abdominal surgery provides excellent pain control when feasible.
Opioid selection considers pharmacokinetic properties and patient-specific factors. Fentanyl offers rapid onset, short duration, and metabolism to inactive compounds, making it ideal for ICU use and particularly in renal impairment. Hydromorphone provides an alternative with intermediate duration, useful for patients requiring sustained analgesia, though caution is needed in renal impairment due to some active metabolite accumulation. Morphine is less preferred due to accumulation of the active metabolite morphine-6-glucuronide in renal failure, causing prolonged sedation and respiratory depression. Remifentanil offers ultra-short action for procedures or when rapid neurological assessment is needed, but requires continuous infusion.
Non-opioid options reduce opioid requirements and provide complementary mechanisms. Acetaminophen administered intravenously or enterally provides effective analgesia for mild to moderate pain and opioid-sparing effects. Ketamine at sub-anesthetic doses provides analgesia and opioid-sparing benefits while avoiding respiratory depression; it may be particularly useful in opioid-tolerant patients. NSAIDs and COX-2 inhibitors are generally avoided in critically ill patients due to renal, gastrointestinal, and cardiovascular risks. Dexmedetomidine, primarily a sedative, has analgesic properties that complement opioid therapy. Regional techniques including epidural catheters and nerve blocks provide excellent analgesia for appropriate surgical populations.
<image>Figure 4. Pain Management in the ICU. Panel A describes assessment tools including numeric rating scale for communicative patients and behavioral tools (BPS, CPOT) for non-communicative patients with scoring interpretation. Panel B outlines analgesia-first principles including addressing pain before sedation, recognizing ETT discomfort, preemptive procedural analgesia, and multimodal approaches. Panel C compares opioid options: fentanyl (short-acting, preferred), hydromorphone (intermediate), morphine (avoid in renal failure), and remifentanil (ultra-short). Panel D presents non-opioid options including acetaminophen, ketamine, limited NSAID use, dexmedetomidine analgesic properties, and regional techniques.</image>
V. Sedation in the ICU
Sedation goals in the modern ICU target light sedation that maintains patient comfort while preserving the ability to interact and participate in care. The Richmond Agitation-Sedation Scale (RASS) provides a validated 10-point scale from +4 (combative) through 0 (alert and calm) to -5 (unarousable). Typical target RASS is -2 (light sedation, brief awakening to voice) to 0 (calm, alert), allowing patients to follow commands and participate in rehabilitation. Deep sedation (RASS -4 or -5) is reserved for specific indications including refractory intracranial hypertension, prone positioning in severe ARDS, therapeutic hypothermia, and during neuromuscular blockade. The Sedation-Agitation Scale (SAS) provides an alternative 7-point assessment tool with similar applications.
Sedative agent selection considers the clinical situation, desired depth and duration, and patient-specific factors. Propofol provides rapid onset and offset with easy titration, making it ideal for patients requiring light sedation with frequent neurological assessment. Hypotension limits use in hemodynamically unstable patients, and prolonged high-dose infusion risks propofol infusion syndrome. Dexmedetomidine, an alpha-2 agonist, produces light sedation with preserved respiratory drive, is associated with less delirium than benzodiazepines, and has analgesic properties. Bradycardia and hypotension can occur. Midazolam provides anxiolysis and amnesia but accumulates with prolonged use, prolongs mechanical ventilation, and increases delirium risk compared to propofol and dexmedetomidine.
Ketamine has emerged as a useful adjunct sedative in selected populations. Its dissociative sedation preserves respiratory drive and hemodynamics, making it useful in hypotensive patients. Bronchodilator properties benefit patients with reactive airway disease. Opioid-sparing analgesic effects reduce total opioid requirements. Traditional concerns about increased intracranial pressure are not supported by current evidence when adequate ventilation is maintained. Ketamine may be used as the primary sedative or as an adjunct to reduce propofol or opioid doses.
Daily spontaneous awakening trials (SAT) represent a cornerstone of sedation management. SAT involves interrupting sedative infusions each morning to assess neurological status and sedation needs. Patients who tolerate awakening without agitation or distress may not need their sedation restarted at the prior rate. SAT identifies over-sedation and enables more rapid weaning. Coordination with spontaneous breathing trials (SAT before SBT) improves outcomes beyond either intervention alone. Safety considerations include ensuring adequate analgesia, staff presence at bedside, and clear resumption criteria if the trial fails.
<image>Figure 5. Sedation in the ICU. Panel A presents sedation goals using RASS with typical targets of -2 to 0, reserving deep sedation for specific indications including prone positioning and neuromuscular blockade. Panel B compares sedative agents: propofol (rapid titration, hypotension risk), dexmedetomidine (light sedation, less delirium), and midazolam (accumulates, increases delirium). Panel C describes ketamine's role with preserved hemodynamics, bronchodilation, and opioid-sparing effects. Panel D outlines daily awakening trials including protocol, coordination with breathing trials, safety considerations, and outcome benefits.</image>
VI. ICU Delirium
Delirium is an acute disturbance of attention and cognition with fluctuating course that affects the majority of mechanically ventilated ICU patients. Hyperactive delirium presents with agitation, hallucinations, and combativeness, making it easily recognized but comprising only a minority of cases. Hypoactive delirium manifests as quiet inattention and withdrawal, is easily missed without systematic screening, and is associated with worse outcomes. Mixed delirium shows features of both subtypes. Prevalence estimates suggest that up to 80% of mechanically ventilated patients experience delirium during their ICU stay, with significant implications for mortality, cognitive outcomes, and resource utilization.
Assessment for delirium requires validated screening tools applied systematically. The Confusion Assessment Method for the ICU (CAM-ICU) is the most widely used tool, assessing four features: acute onset or fluctuating course, inattention, altered level of consciousness, and disorganized thinking. Delirium is present when features 1 and 2 are positive, plus either feature 3 or 4. The Intensive Care Delirium Screening Checklist (ICDSC) provides an alternative 8-item checklist scored over a nursing shift. Screening should occur at least once per shift to detect the fluctuating nature of delirium. Documentation enables tracking of delirium duration and assessment of interventions.
Risk factors for ICU delirium include both modifiable and non-modifiable elements. Non-modifiable factors include advanced age, pre-existing cognitive impairment or dementia, prior delirium, and critical illness severity. Modifiable factors targeted by prevention strategies include sedative exposure (particularly benzodiazepines), sleep deprivation, immobility, sensory deprivation (glasses and hearing aids removed), and metabolic derangements. Infection, medications, and physiological stressors precipitate delirium in predisposed patients. Identifying high-risk patients enables targeted prevention efforts.
Prevention and treatment of delirium employ multi-component strategies. The ABCDEF bundle provides a comprehensive framework addressing multiple delirium risk factors. Minimizing benzodiazepine use by favoring propofol or dexmedetomidine reduces delirium incidence. Sleep hygiene protocols including nighttime light reduction, clustering of care to minimize interruptions, and avoiding unnecessary nocturnal procedures improve sleep quality. Early mobilization gets patients out of bed and engaging with their environment. Reorientation and cognitive stimulation, including family involvement, glasses, and hearing aids, maintain cognitive engagement. Antipsychotics such as haloperidol have been used for symptomatic treatment of agitated delirium, though randomized trials have not demonstrated benefit for delirium prevention or treatment; their role is limited to managing dangerous agitation when non-pharmacological measures fail.
<image>Figure 6. ICU Delirium. Panel A describes delirium subtypes: hyperactive (agitated, obvious), hypoactive (quiet, easily missed), and mixed, noting the high prevalence in ventilated patients. Panel B presents assessment tools including CAM-ICU with its four features and ICDSC, emphasizing systematic screening each shift. Panel C categorizes risk factors into non-modifiable (age, dementia, prior delirium) and modifiable (sedatives, sleep, immobility, sensory deprivation, metabolic). Panel D outlines prevention and treatment with ABCDEF bundle, minimizing benzodiazepines, sleep hygiene, mobilization, reorientation, and limited role of antipsychotics.</image>
VII. Early Mobilization
Early mobilization benefits extend across multiple domains of ICU outcomes. Delirium incidence and duration are reduced through cognitive engagement and maintenance of circadian rhythms. ICU and hospital length of stay decrease with mobility programs compared to usual care. Physical function at discharge improves when mobility begins early in the ICU course. Mechanical ventilation duration may be shortened through improved respiratory muscle function and weaning success. Long-term functional outcomes and quality of life are enhanced by preservation of strength and function during critical illness.
Mobility progression follows a structured approach beginning with passive interventions and advancing based on patient tolerance. Level 1 includes passive range of motion exercises performed by therapists or nurses for patients unable to participate actively. Level 2 advances to active range of motion exercises in bed, engaging patients in movement within their tolerance. Level 3 involves sitting at the edge of the bed with assistance, a major milestone in mobility progression. Level 4 includes transfer from bed to chair with varying degrees of assistance. Level 5 achieves standing at the bedside with support and weight bearing. Level 6 accomplishes ambulation with appropriate assistance and equipment.
Safety considerations guide progression while avoiding excessive restriction of potentially beneficial activity. Lines and tubes should be secured before mobility but do not preclude activity; central lines, arterial lines, and even endotracheal tubes can be safely managed during mobility with appropriate precautions. Hemodynamic stability, generally defined as stable vital signs on low-dose or no vasopressors, should be achieved before significant mobility attempts. Adequate oxygenation on FiO2 below 0.6 ensures tolerance of increased metabolic demands. Adequate staffing with trained personnel enables safe patient handling. Continuous monitoring during activity identifies distress requiring return to rest.
Team approach coordination optimizes the effectiveness of mobility programs. Physical and occupational therapists provide expert assessment and guide progression decisions. Nursing staff incorporate mobility into daily care routines and reinforce gains between therapy sessions. Respiratory therapists ensure ventilator settings support mobility and manage airway during activity. Physicians write mobility orders and oversee the overall plan. Family members provide encouragement and support, increasing patient motivation and engagement. Daily interdisciplinary discussion of mobility goals ensures team alignment.
<image>Figure 7. Early Mobilization. Panel A presents benefits including reduced delirium, shorter ICU stay, improved function, potentially shorter ventilation duration, and better long-term outcomes. Panel B outlines mobility progression levels from passive ROM through active in-bed exercises, edge of bed sitting, transfer to chair, standing, and ambulation. Panel C describes safety considerations including line management, hemodynamic stability requirements, oxygenation thresholds, staffing needs, and monitoring during activity. Panel D emphasizes team approach with roles for PT/OT, nursing, respiratory therapy, physicians, and family in coordinated mobility programs.</image>
VIII. ICU-Acquired Weakness
ICU-acquired weakness (ICUAW) describes significant neuromuscular dysfunction developing during critical illness without alternative explanation. Critical illness polyneuropathy (CIP) involves primarily axonal sensorimotor polyneuropathy with distal more than proximal weakness. Critical illness myopathy (CIM) involves primary muscle dysfunction with proximal weakness and may have better recovery potential than CIP. Combined CIP/CIM is common, and distinction may not be clinically important. Prevalence estimates suggest that 25-50% of patients with prolonged ICU stays develop significant weakness, with profound implications for weaning from mechanical ventilation, rehabilitation, and long-term function.
Multiple risk factors contribute to ICUAW development. Sepsis and multi-organ failure create the metabolic and inflammatory environment conducive to neuromuscular injury. Corticosteroid exposure, particularly high-dose or prolonged use, contributes to myopathy risk. Neuromuscular blocking agents, especially when combined with corticosteroids, increase weakness risk. Hyperglycemia is associated with ICUAW, providing rationale for glucose control though optimal targets remain debated. Immobility allows disuse atrophy to compound the effects of other risk factors. Duration of mechanical ventilation correlates with ICUAW risk, reflecting both severity and cumulative exposure to risk factors.
Diagnosis of ICUAW begins with clinical assessment. Symmetric, flaccid weakness affecting proximal and distal muscles without sensory loss characterizes the syndrome. The Medical Research Council (MRC) sum score tests strength in three muscle groups bilaterally in upper and lower extremities, with scores below 48 out of 60 defining ICUAW. Formal testing requires patient cooperation and may not be possible in sedated or encephalopathic patients. Electromyography and nerve conduction studies distinguish CIP from CIM when this distinction is clinically relevant. Exclusion of other causes of weakness including stroke, spinal cord injury, and myasthenia gravis is necessary.
Prevention and management strategies address modifiable risk factors and promote recovery. Early mobilization is the most important intervention, preserving muscle mass and function despite critical illness. Minimizing sedation enables participation in rehabilitation and avoids sedation-related immobility. Limiting corticosteroid use to appropriate indications and doses reduces one contributor. Glucose control targeting levels below 180 mg/dL provides potential benefit without hypoglycemia risk. Adequate protein nutrition supports muscle preservation and recovery. Ongoing rehabilitation through physical and occupational therapy continues after acute illness, with recovery occurring over weeks to months.
<image>Figure 8. ICU-Acquired Weakness. Panel A defines ICUAW including CIP (axonal polyneuropathy, distal weakness), CIM (primary myopathy, proximal weakness), and combined forms, noting 25-50% prevalence in prolonged ICU stays. Panel B lists risk factors: sepsis, corticosteroids, neuromuscular blockers, hyperglycemia, immobility, and prolonged ventilation. Panel C describes diagnosis using MRC sum score (below 48 defines ICUAW), EMG/NCS for distinguishing subtypes, and exclusion of alternative causes. Panel D presents prevention and management: early mobility (most important), minimize sedation, limit corticosteroids, glucose control, protein nutrition, and ongoing rehabilitation.</image>
IX. Sleep in the ICU
Sleep disruption in the ICU is nearly universal and results from multiple environmental and physiological factors. Noise from alarms, equipment, conversations, and general ICU activity fragments sleep throughout the night. Continuous lighting disrupts circadian rhythms that depend on light-dark cycles. Frequent patient care interventions for vital signs, medications, and assessments interrupt sleep. Medications including sedatives and opioids alter sleep architecture, often reducing restorative sleep stages. The underlying critical illness with pain, dyspnea, and anxiety contributes to poor sleep independent of environmental factors.
Consequences of sleep deprivation extend beyond subjective discomfort. Delirium risk increases with sleep deprivation, potentially through cognitive and attentional effects. Immune function may be impaired, affecting infection resistance and recovery. Overall recovery from critical illness is potentially delayed by inadequate sleep. Patient experience and satisfaction suffer from exhaustion and discomfort. These consequences provide rationale for systematic attention to sleep quality as a component of comprehensive ICU care.
Improvement strategies target modifiable contributors to sleep disruption. Noise reduction through limiting unnecessary conversations, using headphones for patients, providing earplugs, and implementing quiet time periods decreases auditory disruption. Light control with dimming overnight, providing eye masks, and maintaining daytime brightness reinforces circadian rhythms. Clustering care to minimize nighttime interruptions consolidates rest periods. Medication timing avoids unnecessary nocturnal administration when medications can be given during day hours. Sleep protocols systematically implement these interventions as bundled care elements.
Monitoring sleep quality guides interventions and identifies patients struggling with rest. Subjective patient report, when possible, provides direct assessment of perceived sleep quality. Nursing observation notes sleep duration and interruptions. Attention to day-night patterns identifies patients with reversed or absent circadian rhythms. Formal polysomnography is impractical in routine ICU care but research studies document the severe sleep fragmentation and architecture disruption common in critically ill patients. These findings support the importance of sleep-promoting interventions even when formal measurement is not feasible.
<image>Figure 9. Sleep in the ICU. Panel A describes causes of sleep disruption including noise (alarms, conversations), continuous lighting, frequent interventions, medication effects, and underlying illness. Panel B presents consequences including increased delirium risk, impaired immune function, delayed recovery, and poor patient experience. Panel C outlines improvement strategies: noise reduction (earplugs, quiet times), light control (dimming, eye masks), clustering care, medication timing, and sleep protocols. Panel D addresses monitoring through patient report, nursing observation, day-night pattern attention, and research evidence supporting intervention importance.</image>
X. ABCDEF Bundle Integration
The ABCDEF bundle provides a comprehensive framework integrating evidence-based practices to improve ICU outcomes. A stands for Assess, prevent, and manage pain using validated tools and analgesia-first approaches. B encompasses Both spontaneous awakening trials (SAT) and spontaneous breathing trials (SBT), with coordination to maximize benefit. C addresses Choice of analgesia and sedation, favoring lighter sedation and avoiding benzodiazepines when possible. D stands for Delirium assessment, prevention, and management through systematic screening and multi-component interventions. E promotes Early mobility and exercise starting from ICU admission. F recognizes Family engagement and empowerment as essential components of patient-centered care.
Implementation requires systematic processes integrated into daily ICU workflow. Daily assessment of each bundle element during rounds ensures consistent attention to all components. Coordination between elements, particularly SAT before SBT, maximizes synergistic effects. Documentation of bundle compliance enables tracking and quality improvement. Protocols standardize care delivery while allowing for individual patient considerations. Electronic health record integration with reminders and checklists supports consistent implementation.
Outcomes associated with ABCDEF bundle implementation demonstrate meaningful improvements across multiple domains. Delirium incidence and duration decrease when bundle elements are consistently applied. Ventilator-free days increase, reflecting faster weaning success. ICU and hospital length of stay may decrease with comprehensive bundle implementation. Mortality benefits have been suggested in observational studies, though randomized trial evidence is limited. Functional outcomes and quality of life after discharge may improve with early mobilization and delirium prevention.
Barriers to bundle implementation exist but can be overcome with systematic approaches. Cultural resistance to changing established practices requires education about evidence and visible leadership support. Staffing constraints may limit mobility programs; creative solutions including mobility technicians and family assistance can help. Sedation culture favoring deep sedation for patient safety must shift toward recognition of harms from over-sedation. Time constraints during busy shifts challenge consistent bundle attention; efficient protocols and team coordination maximize limited time. Champion identification and ongoing quality monitoring sustain implementation gains.
<image>Figure 10. ABCDEF Bundle Integration. Panel A defines each bundle element: A (pain assessment and management), B (awakening and breathing coordination), C (sedation choice), D (delirium prevention), E (early mobility), F (family engagement). Panel B describes implementation including daily assessment, element coordination, documentation, protocols, and EHR integration. Panel C presents outcomes: reduced delirium, more ventilator-free days, shorter stay, possible mortality benefit, and improved function. Panel D addresses barriers including cultural resistance, staffing, sedation culture, and time constraints with strategies to overcome each.</image>
Summary
Nutritional assessment in critically ill patients uses clinical evaluation and validated screening tools (NRS-2002, NUTRIC) rather than unreliable laboratory markers; caloric targets of 25-30 kcal/kg/day and protein of 1.2-2.0 g/kg/day are achieved through early enteral nutrition within 24-48 hours when possible. Parenteral nutrition is reserved for patients with non-functioning GI tracts, with attention to complications including hyperglycemia, infection, and refeeding syndrome in malnourished patients. Pain management uses validated behavioral tools (BPS, CPOT) for non-communicative patients, following analgesia-first principles with fentanyl as the preferred opioid and multimodal approaches reducing opioid requirements. Sedation targets light levels (RASS -2 to 0) using propofol or dexmedetomidine over benzodiazepines, with daily spontaneous awakening trials coordinated with breathing trials. ICU delirium affects up to 80% of ventilated patients and is detected through systematic CAM-ICU screening; prevention addresses modifiable risk factors including benzodiazepines, sleep disruption, and immobility. Early mobilization reduces delirium, shortens ICU stay, and improves function through progressive activity from passive ROM through ambulation with appropriate safety monitoring. ICU-acquired weakness develops in 25-50% of prolonged ICU stays, prevented primarily through early mobilization, sedation minimization, and attention to modifiable risk factors. Sleep disruption is addressed through noise reduction, light control, and care clustering. The ABCDEF bundle integrates these elements into a comprehensive liberation strategy.
Key Terms
NRS-2002 (Nutritional Risk Screening): A validated tool for identifying patients at nutritional risk based on nutritional status impairment and disease severity.
Refeeding Syndrome: Potentially fatal shifts in fluids and electrolytes (hypophosphatemia, hypokalemia, hypomagnesemia) occurring when nutrition is reintroduced in malnourished patients; prevented by gradual advancement and electrolyte monitoring.
RASS (Richmond Agitation-Sedation Scale): A 10-point scale from +4 (combative) to -5 (unarousable) used to assess and target sedation depth in ICU patients.
SAT (Spontaneous Awakening Trial): Daily interruption of sedative infusions to assess neurological status and sedation requirements, reducing over-sedation and improving outcomes.
CAM-ICU (Confusion Assessment Method for ICU): A validated tool for detecting delirium in ICU patients by assessing acute onset, inattention, altered consciousness, and disorganized thinking.
CIP (Critical Illness Polyneuropathy): A complication of critical illness involving axonal sensorimotor polyneuropathy causing weakness, particularly affecting distal muscles.
CIM (Critical Illness Myopathy): A complication of critical illness involving primary muscle dysfunction causing weakness, particularly affecting proximal muscles.
ABCDEF Bundle: A comprehensive ICU liberation protocol addressing pain Assessment, Both awakening and Breathing trials, Choice of sedation, Delirium management, Early mobility, and Family engagement.
This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.
